PBLS Parabilis Medicines, Inc. - Common Stock
$39.87
Price · Aug 19, 2026
Fundamentals as of Aug 13, 2026
52W Range
$25–$40
97% of range
Analyst Rating
STRONG BUY
10 analysts
Price Target
$42
+5% upside
P/E (TTM)
—
ROE
—
Net Profit Margin
—
PBLS Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$39.87
Market Cap
—
P/E (TTM)
—
EPS (TTM)
—
Revenue (TTM)
—
Div Yield
—
ROE
—
Debt/Equity
—
52W Range
$25 – $40
PBLS Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Configure
10-Year Performance Revenue, net income, margins and EPS trends
Revenue & Net Income
—
EPS
—
Free Cash Flow
—
Margins
—
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Metric
5Y trend
PBLS
Peer Median
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Metric
5Y trend
PBLS
Peer Median
Financial Health Debt, liquidity, solvency — balance sheet strength
Metric
5Y trend
PBLS
Peer Median
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Metric
5Y trend
PBLS
Peer Median
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Metric
5Y trend
PBLS
Peer Median
PBLS Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
BUY
10 analysts
- Strong Buy 5 50.0%
- Buy 4 40.0%
- Hold 1 10.0%
- Sell 0 0.0%
- Strong Sell 0 0.0%
12-Month Price Target
4 analysts · 2026-08-15
Median
$41.00
Mean
$41.75
← Below all targets
$39.87
Low
$40.00
High
$45.00
Median target
$41.00
+2.8%
Mean target
$41.75
+4.7%
Peer comparison (GICS sub-industry) Key metrics vs sector peers
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| PBLS | — | — | — | — | — | — |
| TVTX | $3.47B | -131.8 | 110.5% | -5.2% | -34.6% | — |
| PTCT | $6.19B | 9.8 | 114.5% | 39.4% | -331.5% | — |
| ACAD | $4.55B | 11.6 | 11.9% | 36.5% | 38.1% | — |
| DYN | $3.23B | -5.6 | — | — | -57.8% | — |
| RLAY | $1.47B | -5.3 | 53.4% | -1800.6% | -44.9% | — |
| CELC | $4.81B | -26.3 | — | — | -244.3% | — |
| TNGX | $1.20B | -10.2 | 48.3% | -162.8% | -42.2% | — |
| LEGN | — | — | — | — | — | — |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement 12
| Metric | Trend | Q2 2026 |
|---|---|---|
| Revenue | $148.0K | |
| R&D Expense | $39M | |
| SG&A Expense | $12M | |
| Operating Expenses | $51M | |
| Operating Income | $-51M | |
| Other Non-op | $-2M | |
| Net Income | $-52M | |
| EPS (Basic) | $-2.32 | |
| EPS (Diluted) | $-2.32 | |
| Shares (Basic) | 28,908,277 | |
| Shares (Diluted) | 28,908,277 | |
| EBITDA | $-51M |
Balance Sheet 23
| Metric | Trend | Q2 2026 |
|---|---|---|
| Cash & Equivalents | $1.09B | |
| Short-term Investments | $34M | |
| Prepaid Expense | $5M | |
| Current Assets | $1.13B | |
| PP&E (Net) | $7M | |
| PP&E (Gross) | $21M | |
| Accum. Depreciation | $14M | |
| Total Assets | $1.18B | |
| Accounts Payable | $19M | |
| Accrued Liabilities | $20M | |
| Short-term Debt | $5M | |
| Current Liabilities | $63M | |
| Capital Leases | $32M | |
| Total Liabilities | $128M | |
| Long-term Debt | $6M | |
| Total Debt | $11M | |
| Common Stock | $12.0K | |
| Paid-in Capital | $1.69B | |
| Retained Earnings | $-639M | |
| AOCI | $-18.0K | |
| Stockholders' Equity | $1.05B | |
| Liabilities + Equity | $1.18B | |
| Shares Outstanding | 121,938,652 |
Cash Flow 1
| Metric | Trend | Q2 2026 |
|---|---|---|
| D&A | $600.0K |
Profitability 5
| Metric | Trend | Q2 2026 |
|---|---|---|
| Operating Margin | -34382.4% | |
| Net Margin | -35448.0% | |
| EBITDA Margin | -34382.4% | |
| ROA | -8.9% | |
| ROE | -10.0% |
Liquidity & Solvency 4
| Metric | Trend | Q2 2026 |
|---|---|---|
| Current Ratio | 17.9 | |
| Quick Ratio | 17.8 | |
| Debt / Equity | 0.0 | |
| LT Debt / Equity | 0.0 |
Efficiency 1
| Metric | Trend | Q2 2026 |
|---|---|---|
| Asset Turnover | 0.0 |
Valuation (TTM) 5
| Metric | Trend | Q2 2026 |
|---|---|---|
| Market Cap | $3.34B | |
| Enterprise Value | $2.23B | |
| P/B | 3.2 | |
| P / Tangible Book | 3.2 | |
| EV / EBITDA | -43.8 |
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
My Metrics Your personal watchlist — selected rows from Full Fundamentals
📊
Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Company insiders 7 insiders · 0 officers · 7 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Alan Sebulsky | Director | June 15, 2026 P | 30,000 | 4 | 0 | $723,558 |
| Alexis Borisy | Director | June 11, 2026 C | 105,414 | 0 | 0 | $0 |
| Edward M Fitzgerald | Director | June 11, 2026 C | 14,688 | 0 | 0 | $0 |
| Jake Simson | Director | June 9, 2026 A | — | 0 | 0 | $0 |
| Barbara Weber | Director | June 9, 2026 A | — | 0 | 0 | $0 |
| Richard Klausner | Director | June 9, 2026 A | — | 0 | 0 | $0 |
| Krishna Yeshwant | Director | June 9, 2026 A | — | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
Activists & 5%+ owners 1 position
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, RA Capital Healthcare Fund, L.P. | June 18, 2026 | 23.80% | Initial filing | Passive investment | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF ownership Held by 4 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.